DGIdb - IDELALISIB Drug Record

IDELALISIB chembl:CHEMBL2216870 ApprovedAntineoplasticImmunotherapy

Alternate Names:

CAL-101
GS-1101
IDELALISIB
GS-11CAL-101
ZYDELIG
5-FLUORO-3-PHENYL-2-((S)-1-(9H-PURIN-6-YLAMINO)-PROPYL)-3H-QUINAZOLIN-4-ONE
5-FLUORO-3-PHENYL-2-[(1S)-1-(3H-PURIN-6-YLAMINO)PROPYL]QUINAZOLIN-4(3H)-ONE
CAL-101/CAL101
ZYDELIG®
chembl:CHEMBL2216870
chemidplus:870281-82-6
rxcui:1544460
drugbank:09054
pubchem.compound:11625818

Drug Info:

FDA Approval	Chronic lymphocytic leukemia, Follicular B-cell non-Hodgkin lymphoma, Small lymphocytic lymphoma
Drug Class	Small molecule inhibitor
Drug Class	Kinase Inhibitors
Drug Categories	class ia phosphatidylinositol 3-kinase, antagonists & inhibitors
FDA Approval	not approved
Drug Class	Small molecule
Drug Indications	antineoplastic agent
Drug Categories	cytochrome p-450 cyp2b6 inducers (strength unknown)
Drug Categories	cytochrome p-450 cyp2c19 inhibitors (strength unknown)
Drug Categories	cytochrome p-450 cyp2c8 inhibitors (strength unknown)
Drug Categories	cytochrome p-450 cyp2c8 inhibitors (weak)
Drug Categories	cytochrome p-450 cyp3a substrates
Drug Categories	cytochrome p-450 cyp3a4 inducers
Drug Categories	cytochrome p-450 cyp3a4 inducers (strength unknown)
Drug Categories	cytochrome p-450 cyp3a4 inhibitors
Drug Categories	cytochrome p-450 cyp3a4 substrates
Drug Categories	cytochrome p-450 cyp3a4 substrates (strength unknown)
Drug Categories	cytochrome p-450 cyp3a4 substrates with a narrow therapeutic index
Drug Categories	cytochrome p-450 cyp3a5 inhibitors
Drug Categories	cytochrome p-450 cyp3a5 inhibitors (strength unknown)
Drug Categories	cytochrome p-450 cyp3a5 substrates
Drug Categories	cytochrome p-450 cyp3a7 inhibitors
Drug Categories	cytochrome p-450 cyp3a7 inhibitors (strength unknown)
Drug Categories	cytochrome p-450 cyp3a7 substrates
Drug Categories	cytochrome p-450 enzyme inducers
Drug Categories	cytochrome p-450 enzyme inhibitors
Drug Categories	cytochrome p-450 substrates
Drug Categories	hepatotoxic agents
Drug Categories	heterocyclic compounds, fused-ring
Drug Categories	kinase inhibitor
Drug Categories	oatp1b1/slco1b1 inhibitors
Drug Categories	oatp1b3 inhibitors
Drug Categories	p-glycoprotein inhibitors
Drug Categories	p-glycoprotein substrates
Drug Categories	ugt1a4 inhibitors
Drug Categories	ugt1a4 substrates

(6 More Sources)

Publications:

Sweetlove et al., 2015, Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth., Front Oncol
Shiver et al., 2015, Response to Idelalisib in a Patient with Stage IV Merkel-Cell Carcinoma., N. Engl. J. Med.
Yahiaoui et al., 2017, PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors., PLoS ONE

IDELALISIB PIK3CA

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

Publications:

Sweetlove et al., 2015, Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth., Front Oncol

Shiver et al., 2015, Response to Idelalisib in a Patient with Stage IV Merkel-Cell Carcinoma., N. Engl. J. Med.

IDELALISIB PIK3CD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name CAL-101

Novel drug target Novel Target

Mechanism of Interaction PI3-kinase p110-delta subunit inhibitor

Publications:
IDELALISIB PIK3CG

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

Publications:
IDELALISIB PIK3CB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

Publications:

IDELALISIB PTEN

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Idelalisib + MK2206

Indication/Tumor Type diffuse large B-cell lymphoma

Response Type predicted – sensitive

Publications:

Yahiaoui et al., 2017, PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors., PLoS ONE

IDELALISIB BRAF

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type melanoma

Response Type no benefit

Approval Status Preclinical

Publications:

Sweetlove et al., 2015, Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth., Front Oncol

MyCancerGenome: IDELALISIB
- Version: 20-Jun-2017
Alternate Names:

ICOTINIB Generic Name

ZYDELIG Trade Name

Drug Info:

Drug Class Small molecule inhibitor

FDA Approval Chronic lymphocytic leukemia, Follicular B-cell non-Hodgkin lymphoma, Small lymphocytic lymphoma

Publications:
MyCancerGenome: CAL-101
- Version: 20-Jun-2017
Alternate Names:

CAL-101 Development Name

GS-1101 Development Name

Drug Info:

Drug Class Kinase Inhibitors

Publications:
DrugBank: DB09054
- Version: 5.1.7
Alternate Names:

IDELALISIB DrugBank Drug Name

870281-82-6 CAS Number

Zydelig Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Categories antineoplastic agents

Publications:
TdgClinicalTrial: CAL-101
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small molecule

FDA Approval not approved

Publications:

JAX-CKB: Idelalisib

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Yahiaoui et al., 2017, PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors., PLoS ONE

Sweetlove et al., 2015, Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth., Front Oncol

CIViC: IDELALISIB
- Version: 14-September-2020
Alternate Names:

Drug Info:

Publications:

Shiver et al., 2015, Response to Idelalisib in a Patient with Stage IV Merkel-Cell Carcinoma., N. Engl. J. Med.
GuideToPharmacology: 178103352
- Version: 29-September-2020
Alternate Names:

IDELALISIB GuideToPharmacology Ligand Name

Drug Info:

Publications:
TTD: Idelalisib
- Version: 2020.06.01
Alternate Names:

D0J5VR TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL2216870
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL2216870
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Direct Interaction?	False
Endogenous Drug?	False
Specific Action of the Ligand	Inhibition

Trial Name	CAL-101
Novel drug target	Novel Target
Mechanism of Interaction	PI3-kinase p110-delta subunit inhibitor

combination therapy	Idelalisib + MK2206
Indication/Tumor Type	diffuse large B-cell lymphoma
Response Type	predicted – sensitive

Indication/Tumor Type	melanoma
Response Type	no benefit
Approval Status	Preclinical

IDELALISIB	DrugBank Drug Name
870281-82-6	CAS Number
Zydelig	Drug Brand

Drug Type	small molecule
Drug Groups	approved
Drug Categories	antineoplastic agents

ICOTINIB	Generic Name
ZYDELIG	Trade Name

IDELALISIB Drug Record

IDELALISIB chembl:CHEMBL2216870 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

IDELALISIB PIK3CA

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction? False Endogenous Drug? False Specific Action of the Ligand Inhibition

Publications: Sweetlove et al., 2015, Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth., Front Oncol Shiver et al., 2015, Response to Idelalisib in a Patient with Stage IV Merkel-Cell Carcinoma., N. Engl. J. Med.

IDELALISIB PIK3CD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name CAL-101 Novel drug target Novel Target Mechanism of Interaction PI3-kinase p110-delta subunit inhibitor

Publications:

IDELALISIB PIK3CG

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? False

Publications:

IDELALISIB PIK3CB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? False

Publications:

IDELALISIB PTEN

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Idelalisib + MK2206 Indication/Tumor Type diffuse large B-cell lymphoma Response Type predicted – sensitive

Publications: Yahiaoui et al., 2017, PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors., PLoS ONE

IDELALISIB BRAF

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type melanoma Response Type no benefit Approval Status Preclinical

Publications: Sweetlove et al., 2015, Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth., Front Oncol

MyCancerGenome: IDELALISIB

Alternate Names: ICOTINIB Generic Name ZYDELIG Trade Name

Drug Info: Drug Class Small molecule inhibitor FDA Approval Chronic lymphocytic leukemia, Follicular B-cell non-Hodgkin lymphoma, Small lymphocytic lymphoma

Publications:

MyCancerGenome: CAL-101

Alternate Names: CAL-101 Development Name GS-1101 Development Name

Drug Info: Drug Class Kinase Inhibitors

Publications:

DrugBank: DB09054

Alternate Names: IDELALISIB DrugBank Drug Name 870281-82-6 CAS Number Zydelig Drug Brand

Drug Info: Drug Type small molecule Drug Groups approved Drug Categories antineoplastic agents

Publications:

TdgClinicalTrial: CAL-101

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class Small molecule FDA Approval not approved

Publications:

JAX-CKB: Idelalisib

Alternate Names:

Drug Info:

CIViC: IDELALISIB

Alternate Names:

Drug Info:

Publications: Shiver et al., 2015, Response to Idelalisib in a Patient with Stage IV Merkel-Cell Carcinoma., N. Engl. J. Med.

GuideToPharmacology: 178103352

Alternate Names: IDELALISIB GuideToPharmacology Ligand Name

Drug Info:

Publications:

TTD: Idelalisib

Alternate Names: D0J5VR TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL2216870

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL2216870

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

Publications:

Sweetlove et al., 2015, Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth., Front Oncol

Shiver et al., 2015, Response to Idelalisib in a Patient with Stage IV Merkel-Cell Carcinoma., N. Engl. J. Med.

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name CAL-101

Novel drug target Novel Target

Mechanism of Interaction PI3-kinase p110-delta subunit inhibitor

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Idelalisib + MK2206

Indication/Tumor Type diffuse large B-cell lymphoma

Response Type predicted – sensitive

Publications:

Yahiaoui et al., 2017, PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors., PLoS ONE

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type melanoma

Response Type no benefit

Approval Status Preclinical

Publications:

Sweetlove et al., 2015, Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth., Front Oncol

Alternate Names:

ICOTINIB Generic Name

ZYDELIG Trade Name

Drug Info:

Drug Class Small molecule inhibitor

FDA Approval Chronic lymphocytic leukemia, Follicular B-cell non-Hodgkin lymphoma, Small lymphocytic lymphoma

Alternate Names:

CAL-101 Development Name

GS-1101 Development Name

Drug Info:

Drug Class Kinase Inhibitors

Alternate Names:

IDELALISIB DrugBank Drug Name

870281-82-6 CAS Number

Zydelig Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Categories antineoplastic agents

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small molecule

FDA Approval not approved

Publications:

Shiver et al., 2015, Response to Idelalisib in a Patient with Stage IV Merkel-Cell Carcinoma., N. Engl. J. Med.

Alternate Names:

IDELALISIB GuideToPharmacology Ligand Name

Alternate Names:

D0J5VR TTD Drug ID